The deal, announced June 17, includes a cash offer of $10.50 per share for all outstanding Verve stock. Lilly may also pay as ...

Eli Lilly will buy Boston-based Verve Therapeutics, Inc. in a billion dollar deal with plans to advance Verve's new line of ...

Eli Lilly agreed to acquire Verve Therapeutics for about $1 billion upfront, adding a potential treatment for cardiovascular ...

Eli Lilly announced that the highest doses of tirzepatide (Zepbound) -- 12.5 mg and 15 mg -- will soon be available in single ...

The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment ...

Eli Lilly's $1.3B acquisition of Verve Therapeutics caused a sharp rally, but with shares above the buyout price, I recommend ...

B Verve Therapeutics (VERV) acquisition offers investors a 70%+ premium. See why I think this deal is beneficial to both ...

Eli Lilly has agreed to acquire cardiovascular disease treatment specialist Verve Therapeutics in a deal potentially rising ...

Sunrun (RUN), Plug Power (PLUG), and Array Technologies (ARRY) plunge after the Senate revealed its revisions to President ...

Verve Therapeutics’ stock was rallying by a record 80% on Eli Lilly’s premium purchase price for the drug-development company ...

Eli Lilly has announced that it will be acquiring Verve Therapeutics in a deal worth approximately $1.3bn, marking a ...

With acquisition of Verve Therapeutics, Eli Lilly aims to advance next-generation cardiovascular care through one-time gene ...